Apretude (Long-Acting Injectable Cabotegravir)

Apretude contains cabotegravir, a revolutionary long-acting integrase inhibitor developed for HIV prevention. Unlike daily pills, Apretude is administered as an intramuscular injection every 8 weeks, providing a convenient and discreet way to prevent HIV infection.
FDA-approved in 2021, it has quickly become a popular choice for individuals who prefer not to take daily oral PrEP.
Apretude works by preventing the HIV virus from integrating into human DNA, stopping infection at an early stage. It offers over 99% protection when taken consistently.
The regimen begins with two initiation doses a month apart, followed by injections every two months.
Apretude is ideal for those who struggle with pill adherence or prefer a longer-acting preventive method.
Side effects may include mild injection site pain, fatigue, or fever. Regular HIV testing is required before each injection.